Generation and preliminary characterization of chimeric antibodies against neuraminidase of H7N9 subtype influenza A virus
10.3760/cma.j.issn.1003-9279.2019.02.021
- VernacularTitle: 抗H7N9流感病毒神经氨酸酶嵌合抗体的制备及初步鉴定
- Author:
Feier RUAN
1
;
Lingling CHEN
1
;
Kun QIN
2
;
Mingbin LIU
3
,
4
;
Haiying CHEN
5
;
Jianfang ZHOU
2
Author Information
1. Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, Nanchang 330006, China
2. Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China
3. Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
4. Nanchang Center for Disease Control and Prevention, Nanchang 330038, China
5. Nanchang Center for Disease Control and Prevention, Nanchang 330038, China
- Publication Type:Journal Article
- Keywords:
H7N9;
Neuraminidase;
Chimeric antibody
- From:
Chinese Journal of Experimental and Clinical Virology
2019;33(2):212-216
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To develop the chimeric antibodies against neuraminidase (NA) of H7N9 and to identify their biological activity and function.
Methods:The genes of variable regions of the light chain (VL) and heavy chain (VH) obtained by mouse hybridoma technology were cloned respectively into the expression VH and VL vectors bearing human-derived Cγ1, and Cκ1 and co-transfected into 293T cells. The chimeric antibodies were purified and their functions were investigated.
Results:Two chimeric antibodies, 1E2 and 3E3 against neuraminidase (NA) of H7N9 were obtained. Both antibodies recognized similar antigenic epitopes. MAb 1E2 and 3E3 could prevent the infectivity with H7N9 and H11N9 virus and reduce their size of viral plaque.
Conclusions:The chimeric antibodies specific for N9 could prevent the infection of N9 subtype influenza virus as well as the NAI-resistant mutants and could be a potential immunotherapy approach for H7N9 treatment.
